Global Central Nervous System Partnering Report 2010-2017: Latest Deal Trends, Players and Financials

DUBLIN, September 8, 2017 /PRNewswire/ --

The "Global Central Nervous System Partnering 2010-2017: Deal trends, players and financials" report has been added to Research and Markets' offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Global Central Nervous System Partnering 2010 to 2017 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Central Nervous System deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Central Nervous System deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities.

Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2010. The chapter is organized by specific Central Nervous System therapeutic target.

In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type.

The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope:

    --  Trends in Central Nervous System dealmaking in the biopharma industry
        since 2010
    --  Analysis of Central Nervous System deal structure
    --  Access to headline, upfront, milestone and royalty data
    --  Access to hundreds of Central Nervous System deal contract documents
    --  Comprehensive access to over 3500 Central Nervous System deal records
    --  The leading Central Nervous System deals by value since 2010
    --  Most active Central Nervous System dealmakers since 2010

In Global Central Nervous System Partnering 2010 to 2017, available deals and contracts are listed by:

    --  Headline value
    --  Upfront payment value
    --  Royalty rate value
    --  Stage of development at signing
    --  Deal component type
    --  Technology type

    --  Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking

Chapter 3 -Financial deal terms for Central Nervous System partnering

Chapter 4 - Leading Central Nervous System deals and dealmakers

Chapter 5 - Central Nervous System contract document directory

Chapter 6 - Central Nervous System dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/mlp5nv/global_central

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-central-nervous-system-partnering-report-2010-2017-latest-deal-trends-players-and-financials-300516316.html

SOURCE Research and Markets